Immunovia SEK 100m Capital Raise | Q3 2025

Immunovia in brief 

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer. 
  
USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.  

Press release  

Jeff Borcherding, CEO of Immunovia, comments: 

“In just two years, we have completely transformed Immunovia and developed an entirely new product that outperforms existing surveillance methods. And we're just days away from launch. Both physicians and people at high risk of pancreatic cancer are desperate for better methods for early detection. With strong support from these critical stakeholders, we now enter a fundamentally new phase with the potential to transform both patient outcomes and the company's future. I hope our shareholders will join me in seizing this unique opportunity to participate in a defining chapter for our company.” 

Website: https://immunovia.com/